Filing Flows › Idexx Laboratories (IDXX) › Q2 2026
Idexx Laboratories (IDXX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Idexx Laboratories (IDXX) reported revenue of $1.2B for the second quarter 2026 (Q2 2026), +10% from a year earlier and +7% from the quarter before. Operating margin was 35.0%, net earnings $338M (27.8% of revenue).
Idexx Laboratories, Q2 2026: revenue $1.2B (+10% year over year), operating margin 35.0%, net earnings $338M, operating cash flow $347M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2B | +7% | +10% |
| Gross profit | $779M | +8% | +12% |
| Operating profit | $426M | +17% | +14% |
| Net earnings | $338M | +22% | +15% |
| Operating cash flow | $347M | +30% | +87% |
| Free cash flow | $323M | +38% | +113% |
What changed
Revenue was $1.2B in Q2 2026, up 10% year over year and up 7% from the previous quarter. Product revenue was the largest line at 59% of revenue. Product revenue added $0.06B year over year (up 9%), 57% of the total change.
Gross margin was 64.0%, up 1.4 points from Q2 2025. Operating profit was $0.43B, a 35.0% margin (up 1.4 points year over year). Of the extra revenue versus Q2 2025, 49% reached operating profit, above the 34% margin then. Operating expenses grew 10% against revenue growth of 10%. The fastest-growing cost line was General & admin (+18%). Net earnings were $0.34B, up 15% year over year. The effective tax rate was 18.9%.
Operating cash flow was $0.35B (up 87% year over year), 103% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items used $0.05B. Capital expenditures of $0.02B left free cash flow of $0.32B.
Questions
What was Idexx Laboratories' revenue in the second quarter 2026?
Idexx Laboratories (IDXX) reported revenue of $1.2B for the second quarter 2026 (Q2 2026), +10% from a year earlier and +7% from the quarter before.
Was Idexx Laboratories profitable in the second quarter 2026?
Operating profit was $426M (35.0% of revenue) and net earnings $338M.
Source: Idexx Laboratories 10-Q on SEC EDGAR.